AMRX vs NVDA · P/E 44, rev $2.79B vs P/E 58, rev $96.22B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus NVIDIA Corporation (NVDA) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
NVIDIA Corporation (NVDA) is a semiconductors company listed on US. It is led by Jensen Huang.
Latest reported AMRX revenue for 2024-12-31 was $2.79B. Net income was -$73.9M. Revenue was up 16.7% from 2023-12-31 to 2024-12-31. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported NVDA revenue for 2026-07-26 was $96.22B. Net income was $59.69B. Revenue was up 17.9% from 2026-04-26 to 2026-07-26. NVDA currently screens at market cap $4.40T and trailing P/E 58.2.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. NVDA currently screens at market cap $4.40T and trailing P/E 58.2.
Not investment advice. Open the AMRX and NVDA stock pages for the full models.
Not investment advice.